Factor Associated with Treatment Initiation of Multidrug Resistance Tuberculosis in Jakarta, Indonesia: A Mixed-Method Study

Loading...
Thumbnail Image

Date

2021

Advisors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

1275
views
414
downloads

Abstract

Background: Indonesia has one of the highest TB burdens in the world and is one of ten countries that accounted for 77% of the global gap between treatment enrollment and the estimated number of new cases of MDR/RR-TB in 2019. However, there are knowledge gaps about how the delay of MDR-TB treatment initiation might affect this situation. Therefore, this study aimed to examine challenges of implementing MDR-TB treatment initiation in a Programmatic Management of Drug-Resistant Tuberculosis (PMDT) national referral hospital in Indonesia. Method: This study used mixed methods to collect both quantitative data through hospital records of MDR-TB patients and qualitative data through interviews with patients and health workers. Result: The median time between diagnosis and treatment initiation was 26 days, and was associated with co-morbidities, MDR-TB knowledge, and support assessment. This study also revealed the complex situation of people affected with MDR-TB with lack of social support and health system challenges during the MDR-TB treatment initiation process. Conclusion: The results of this study revealed the challenges of the treatment initiation process from the complex perspectives of the patients, the aspects of the health system that need to be improved, and the importance of social support starting from diagnosis.

Description

Provenance

Citation

Citation

Silitonga, Permata Imani Ima (2021). Factor Associated with Treatment Initiation of Multidrug Resistance Tuberculosis in Jakarta, Indonesia: A Mixed-Method Study. Master's thesis, Duke University. Retrieved from https://hdl.handle.net/10161/23158.

Collections


Dukes student scholarship is made available to the public using a Creative Commons Attribution / Non-commercial / No derivative (CC-BY-NC-ND) license.